Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Amlitelimab in Healthy Volunteers
NCT03161288Phase 1Completed
- Sponsor
- Kymab
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (2 arms), sponsored by Kymab. Primary endpoints: Occurrence of all treatment-related adverse events at Day 92, Changes in vital signs at Day 92 and 4 more. Started May 2017; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03161288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161288.